Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors.

Necroptosis is an important form of programmed cell death (PCD), which is mediated by a death receptor and independent of the caspase proteolytic enzyme. Mixed lineage kinase domain-like (MLKL) is the final effector of necroptosis, playing an irreplaceable role in the execution of necroptosis. However, the studies on MLKL inhibitors are in their infancy. Necrosulfonamide (NSA) is an early-discovered covalent MLKL inhibitor, possessing medium anti-necroptosis activity and a structure-activity relationship (SAR) not widely disclosed. In this study, with the covalent motif maintained, we aim to improve the activity by introducing the terminal fused heterocycles and meanwhile revealing the SAR on the part. As a result, compounds 9 and 14 showed the best activity (EC50 = 148.4 and 595.9 nM) against necroptosis among the analogues by covalently binding to MLKL. The SAR was also concluded to guide further structural optimization in this field. Copyright © 2024 Elsevier Ltd. All rights reserved.

Citation

Yining Tang, Chunlin Zhuang. Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors. Bioorganic & medicinal chemistry. 2024 Mar 15;102:117659

Mesh Tags

Substances

PMID: 38442525

search → result